Avedro announces the expansion of our platform of cross-linking technology with the acquisition of IROC Innocross’ assets.
With this acquisition, Avedro’s cross-linking technology now spans the entire spectrum of corneal cross-linking procedures, from treating corneal pathology with our UV-X devices and MedioCROSS riboflavin–to enhancing LASIK outcomes with our KXL System and VibeX family of riboflavin–to developing non-invasive refractive procedures with our advanced KXL II System.
Dr. Michael Mrochen, founder of IROC Innocross, will join the Avedro team as a member of its Medical Advisory Board.
To read the press release, click here.
IROC Innocross Devices
Avedro’s cross-linking systems and family of riboflavin products are not for sale in the US. MA-00372A